Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.…
Should You Pick Vertex Stock Over Its Biotech Rivals?
Editas Medicine (NASDAQ: EDIT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 1.640 USD on 20 November 2026, down 33.6% over 52 weeks. Its 52-week range is 1.630 USD to 3.940 USD, and it trades at the bottom of that range.
Its market capitalisation is 253.12M USD.
Editas Medicine reports an operating margin of -167.0% and revenue up 37.4% year over year.
It holds more cash than debt, a net cash position of 176.26M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 6.100 USD is 272.0% above the current price. The next earnings report is expected on 8 March 2027.